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IVIG is essential therapy for a rapidly expanding number of
debilitating and life-threatening conditions. The evidence-
based use of IVIG from an American perspective was
reviewed in 2006 by the American Academy of Allergy,
Asthma and Immunology (AAAAI) [1], and has been simi-
larly considered elsewhere [2–4]. The number of clinical
indications supported by at least some experimental evi-
dence, however, is increasing. Future evidence-based lists
of diseases advantageously modified by IVIG are likely to
continue increasing in scope and may eventually include
subsets of patients affected by common debilitating illnesses
such as Alzheimer’s disease [5, 6]. Given the number of
indications for therapeutic immunoglobulin and the diversity
of related clinical fields, careful consideration of the useful-
ness of IVIG in each condition is warranted. Examples for
considering the evidence supporting the use of IVIG do exist
across distinct clinical disciplines [1, 7–9]. Detailed assess-
ment of the value of IVIG within specific clinical areas is
critical, since IVIG is a finite resource derived mostly from
dedicated plasma donations and its production and distribu-
tion are dependent on an increasingly complex set of vari-
ables. Intermittent shortages as well as reimbursement-
related difficulties in access to IVIG have occurred and are
likely to increase if demand continues to rise [10]. In this
light a comprehensive evaluation and demand-based model
has been developed in the UK and is currently active [11].
Furthermore, IVIG is expensive and its administration can be
labor intensive. While costs can be justified [12, 13], the
increasing use of IVIG can place specific burdens on the
healthcare system.
The use of IVIG in many diseases is the standard of care;
in others, its use is supported by reasonable evidence and is
often without effective therapeutic alternatives. The latter
includes a few life-threatening diagnoses, which invariably
lead to premature death without treatment.
Given the multifaceted current and future demands for
IVIG, specific prioritization of evidence-based disease in-
dications may be necessary. This may be particularly rele-
vant if new indications for IVIG result in substantial numbers
of new patients who could potentially benefit from IVIG,
which could place critical stress upon existing supply and
demand. A survey conducted by the Immune Deficiency
Foundation found 27 % of American hospital pharmacists
to already have locally-defined protocols for prioritizing
IVIG indications [14]. Given that there are no specific guide-
lines in place for this process, there is likely to be tremendous
variability amongst institutions and practices. To reduce
inconsistency and promote best practice, we propose an
IVIG prioritization algorithm for strong evidence-based in-
dications (Fig. 1). Specifically, we propose two additional
axes be added for the clinical indications for which there is
evidence to support use. This would, therefore, be on top of
the “first axis” which represents utilization defined by strong
evidence-based medicine. Consequently, the evidence-
supported medical conditions would be additionally consid-
ered and ranked according to the severity of the disease as
well as the availability of effective therapeutic alternatives
(Fig. 1a) as “second” and “third” axes. The highest priority
indication according to this algorithm would be evidence-
supported use that is an immediately life-threatening disease
that does not have reasonable treatment alternatives (Fig. 1b).
Such an indication would score an “A” on the disease severity
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scale for being “immediately life-threatening” and a “1” on the
therapeutic alternatives axis due to their being no efficacious
alternatives to IVIG therapy. Although not without controver-
sy, an example of an “A1” indication might be toxic epidermal
necrolysis in specific subsets of patients [15, 16].
In order to illustrate this algorithm, the authors each
independently considered a list of 8 primary immunodefi-
ciency and 9 other diagnoses and provided their opinion
regarding a disease severity score and efficacy of therapeutic
alternatives score (Table I). These considerations were ap-
plied as the “second” and “third” axes independently of the
“first” axis of evidence-based usage. None of the authors
were aware of the others scores for these additional two axes.
As an exercise it demonstrates that there were a few areas of
consensus, but more commonly minor differences in opin-
ion. In a minority there were substantive differences.
In order to illustrate the role and interplay of the “first”
axis of strong evidence supporting use, the supporting evi-
dence rating and evidence-based recommendation from the
2006 AAAAI IVIG evidence review is provided in Table I
(fourth column). While those recommendations are now
several years old and in need of update, they are provided
as a frame of reference for the “first” axis. This demonstrates
that even within indications supported by similar levels of
evidence, there is typically a range of generally aligned
scores on the “second” and “third” axes of the algorithm.
For example both SCID and CVID have the same level of
evidence and evidence-based recommendation for IVIG
usage, but the disease severity and effectiveness of therapeu-
tic alternatives rankings are discordant (the difference in the
latter for SCID amongst the authors was likely that one
author perceived hematopoietic stem cell transplantation as
an effective “alternative”, while the other two authors did not
perceive this as an alternative to the need for therapeutic
immunoglobulin). Another example of the utility of the
algorithm and use of these additional axes would be in the
comparison of the PID diagnoses such as XLA to ITP. The
use of IVIG in ITP is supported by the highest level of
evidence and the AAAAI recommendation for use is that
of “definitely beneficial”. The evidence for use of IVIG in
XLA is also perceived as “definitely beneficial” in the
AAAAI document but is supported by a lower level of
evidence. The comparison of these two indications by the
authors using algorithm, however, demonstrates distinct dif-
ferences in prioritization in the opposite direction of the
grade of evidence. Thus the quality of evidence alone does
not necessarily provide the full dynamic range of utility of
therapeutic immunoglobulin in specific clinical indications.
It is hoped that the application of the algorithm as “second”
and “third” axes can provide this additional granularity and
resolution that could prove helpful in meeting increased de-
mands for a limited supply of IVIG.
Overall this proposal and exercise demonstrates that were
such an algorithm to be applied at any level (institutional,
regional, or national) there would be a need for consensus
building (which was not part of the exercise in the Table).
Fig. 1 Algorithm for the priori-
tization of evidence-based indi-
cations for IVIG. a Indications
for IVIG based upon experimen-
tal evidence can be considered
according to the severity of the
disease (y-axis) and the efficacy
of therapeutic alternatives to
IVIG (x-axis). Each is based up-
on a 4-point scale leading to 16
potential ratings for an indication
and/or sub-categories of specific
indications. b The prioritization
of specific indications can then
be determined using a linear
scale, which ranks the individual
severity and efficacy of alterna-
tives. The prioritization of the
ratings within each of the indi-
vidual cells from the severity and
alternatives grid is displayed lin-
early from left (high priority) to
right (low priority). Indications
having the same rating should be
considered to be of equal priority
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Ideally this would include involvement of individuals with
academic and clinical expertise appropriate to the different
disease indications under consideration.
As described above, an assumption inherent in this algo-
rithm is that IVIG uses are based upon valid experimental
data. Quality of evidence does constitute a separate axis in
the algorithm, but the authors have chosen not to treat this
“first” axis as continuous. In particular, the use of a contin-
uous “first” axis might introduce an unfair bias against
certain indications for which IVIG is effective, but not sup-
ported by the highest levels of evidence (as emphasized
above). In aggregate, primary immunodeficiency diseases
represent an original indication for immunoglobulin therapy
and will never be amenable to placebo-controlled
Table I Author ratings of primary immunodeficiency and other indications for IVIG
Diseasea Disease Severity Ratingb
(A, B, C, D)
Efficacy of Alternativesc






XLA ABA 221 IIb-B, DBf yes
XHM ABA 221 IIb-B, DB yes
CVID BCA 222 IIb-B, DB yes
SCID AAA 141 IIb-B, DB yes
XLP BBB 232 IIb-B, DB yes
SAD BCC 343 IIb-B, PB yes
IgGSD CCC 344 IIb-B, PB yes
IgA deficiency CDD 434 IV-D, UB no
Other conditions
Toxic Epidermal Necrolysis ABA 141 IIa-B, PB yes
ITP BBB 343 Ia-A, DB yes
Autoimmune hemolytic anemia BCC 343 III-D, MPB maybe
Pemphigus vulgaris CBC 243 III-C, MPB maybe
Kawasaki disease ABA 121 Ia-A, DB yes
Recurrent spontaneous abortion DCD 133 Ia-A, UB no
autism DDD 241 III-C, UB no
CIDP CCC 322 Ia-A, DB yes
PANDAS CCC 341 IIb-B, MPB maybe
Each author scored the disease indications listed according to the paradigm in Fig. 1 without knowing the scores provided by the other authors. The
scores listed do not correspond to any particular author order. Consensus scores among the authors are shown in boldface
aXLA X-linked agammaglobulinemia, XHM X-linked hyper IgM syndrome, CVID common variable immunodeficiency, SCID severe combined
immunodeficiency, XLP X-linked lymphoproliferative disease, SAD specific antibody deficiency, IgGSD IgG subclass deficiency, ITP idiopathic
thrombocytopenic purpura, CIDP chronic immune demyelinating polyneuropathy, PANDAS pediatric autoimmune neuropsychiatric disorders
associated with Streptococcal infection
b Severity corresponds to the y-axis in Fig. 1a, where A represents immediately life-threatening, B represents life-threatening, C represents Life-
modifying and D represents other. The three letters listed correspond to the score of each of the three authors
c Efficacy corresponds to the x-axis in Fig. 1a where the score corresponds to the perceived efficacy of therapeutic alternatives to IVG, 1 = none, 2 =
low, 3 = medium, 4 = high. The three numbers are the scores for each of the diseases provided by the individual authors
d As per the text, this algorithm should only be utilized when evidence supports the provision of therapy for the particular condition. The level of
evidence and strength of recommendation from the 2006 IVIG [1] evidence review are listed. The roman numerals (and lowercase letter where
appropriate) denote the evidence category and the hyphenated letter represents the strength of recommendation (see the 2006 document for additional
explanation). The evidence-based recommendation provided in the 2006 evidence review is also listed using the following abbreviations: DB
definitely beneficial, PB probably beneficial, MPB might provide benefit, UB unlikely beneficial
e The application of the algorithm should be reserved for those in which IVIG is recommended based upon the existing evidence, which of course is
subject to change with time. For the purposes of the present algorithm this is divided into three categories: yes – where the supporting evidence is
perceived as definitely or probably beneficial; no – where the supporting evidence is perceived as unlikely to be beneficial; and maybe – where the
supporting evidence is perceived as “might provide benefit”
f It is important to note that in some cases stronger evidence is available now as compared to 2006 and the reader is referred to subsequent revisions of
the 2006 document, alternative documents of similar nature, or the direct evidence
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randomized trials of IVIG because its application represents
standard of care without current therapeutic alternatives to
study. To be effective, however, the prioritization algorithm
would need to be supplemented by rigorous evidence-based
use of IVIG within the specific disease categories for partic-
ular indications. Thus, the use of the algorithm is only
recommended for diseases in which the evidence-based rec-
ommendation for use is graded as definitely, or probably
beneficial (based upon AAAAI recommendations as provid-
ed in the rightmost column of Table I). The algorithm may be
applicable for diseases in which the evidence is perceived as
“may provide benefit”, but is not applicable for diseases in
which evidence is graded as “unlikely to provide benefit”, as
IVIG should not be used to treat those diseases (even though
a few of these were included in Table I to demonstrate how
they would fare on these additional “axes”). How to integrate
the prioritization of the diseases for which IVIG “may pro-
vide benefit” into those where it is perceived as more likely
to provide benefit is complex and should rely upon mean-
ingful dialogue among key academic entities.
In coming years, it is likely that physicians whose patients
now rely on IVIG will need to be proactive and consider
discussion of prioritization in order to enable preparedness
should strain be placed on the supply relative to demand for
IVIG. The patients whose lives can be definitively most
improved and/or preserved by IVIG should be ensured ready
access. Community-wide consideration of this challenge is
most likely to result in a just and rational outcome.
Open Access This article is distributed under the terms of the Creative
Commons Attribution License which permits any use, distribution, and
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